ClinicalTrials.gg
Active, not recruitingNCT04464876Updated May 22, 2024

SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

An interventional study of SATURN TA System in Mitral Regurgitation, Valve Heart Disease and Heart Valve Diseases, sponsored by InnovHeart. Active, not recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by InnovHeart · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Mitral Valve Insufficiency with a site in Denmark — 4 open to participants now, 6 under way, none of them phase 3. Mitral Valve Insufficiency · Denmark.

Planned enrollment
8th of 10
20 · median 98
Started
2020
with 1 other
No phase
9 of 13
2 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
InnovHeart

Among the 13 studies in Mitral Valve Insufficiency with a site in Denmark, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 9 with no phase, and was the 10th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

4 of the 13 studies in Mitral Valve Insufficiency with a site in Denmark are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Mitral Valve Insufficiency with a site in Denmark, or all of them as a file.
02

Study summary

This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who are not suitable for surgical treatment following Heart Team assessment.

03

Conditions studied

  • Mitral Regurgitation
  • Valve Heart Disease
  • Heart Valve Diseases
  • Mitral Valve Disease
  • Mitral Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age 18 years or older.
  2. Severe functional mitral regurgitation (≥ Grade 3+).
  3. functional Class ≥ II. If Class IV, patient must be ambulatory.
  4. Treatment and compliance with optimal guideline-directed medical therapy (GDMT) for heart failure for at least 30 days.
  5. Not a suitable candidate for open mitral valve surgery due to high operative risk, as determined by the Heart Team.
  6. Able to complete quality-of-life assessment (KCCQ).

General Exclusion Criteria:

  1. Excessive frailty or comorbid conditions that preclude the anticipated benefit of the valve replacement.
  2. \<1 yr due to noncardiac conditions.
  3. Active endocarditis.
  4. Active systemic infection.
  5. Modified Rankin Scale ≥4 disability.
  6. Hemodialysis/ chronic renal failure ( \< 35 mL/min/m2).
  7. Pulmonary arterial hypertension (fixed PAS \< 60mmHg). 8) on home oxygen.
  1. Refuses blood transfusions. 10) Documented bleeding or coagulation conditions (hypo- or hyper-coagulable states).
  1. Severe connective tissue disease under chronic or cortisone therapy.
  1. Pregnant/ lactating. Females of childbearing age must be willing to take .
  1. Participating in other studies likely to confound the results or affect the study.
  1. Unable to consent. 15) Unable or unwilling to comply with study Follow-up. 16) Patients classified as "vulnerable patients".

Cardiovascular Exclusion Criteria:

  1. Myocardial infarction during prior 30 days.
  2. Stroke or during prior 30 days.
  3. Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed).
  4. Prior mitral valve treatment (e.g. valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment.
  5. Prior surgical mechanical valve AVR.
  6. Prior TAVI.
  7. Need for any cardiovascular surgery or intervention (other than for MV disease) within 30 days.
  8. CRT or ICD implanted in previous 30 days.
  9. Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure \<90mmHg, Inotropic dependent or IABP/mechanical circulatory support.
  10. CABG or PCI within previous 30 days.
  11. Adequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure. No need for revascularization.
  12. Prior or planned heart transplantation (UNOS status 1).
  13. Physical evidence of right-sided congestive heart failure:

    1. Patients with ascites.
    2. Patients with anasarca (generalized edema / hydropsy).

    Procedural Exclusion Criteria:

  14. Chest condition that prevents transapical access.
  15. Known or to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy).
  16. Documented hypersensitivity to nickel or titanium.

Cardiac Exclusion Criteria (evaluated by Core Labs):

  1. Left ventricular EF ≤ 30% by imaging.
  2. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass.
  3. Extensive mitral flail leaflets.
  4. Left ventricular thrombus, mass, or vegetation.
  5. Left ventricular end-diastolic diameter > 7.5 cm.
  6. Severe right ventricular dysfunction.
  7. Significant intracardiac shunt.
  8. Anatomic ineligibility for SATURN valve as determined by the Screening Committee.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment

    SATURN TA TMVR Device implanted

    Device: SATURN TA System

Interventions

  • DeviceSATURN TA System

    SATURN TA TMVR Device implanted

06

What researchers measure

Primary outcomes

  1. Freedom from device-related or procedure-related major adverse events

    Freedom from device-related or procedure-related major adverse events at 30 days (cardiac death, peri-procedural myocardial infarction, disabling stroke, renal failure requiring dialysis, life threatening bleeding).

    Time frame: 30 days

  2. Reduction of mitral regurgitation

    Reduction of mitral regurgitation to ≤1 at 30 days.

    Time frame: 30 days

  3. Technical success

    Technical success defined as alive patient at exit from procedure room, with all of the following: * Successful access, delivery and retrieval of the delivery systems. * Development and correct positioning of the bioprosthesis. * Freedom of additional emergency surgery or re-intervention related to the device or access procedure.

    Time frame: Day 0

Secondary outcomes

  1. Freedom from device-related or procedure-related major adverse events

    * Freedom from device-related or procedure-related major adverse events throughout long- term follow-up. * Freedom from all-cause mortality

    Time frame: 30 days, 1 year, 2 years

  2. Freedom from all-cause mortality

    Freedom from all-cause mortality

    Time frame: 30 days, 1 year, 2 years

  3. Patients success

    Patients success

    Time frame: 30 days, 1 year, 2 years

  4. Device success

    Device success

    Time frame: 30 days, 1 year, 2 years

  5. 6 Minute Hall Walk Test

    Improvement from baseline in functional status by ≥ 30 meters

    Time frame: 30 days, 1 year, 2 years

  6. KCCQ

    Improvement from baseline in Quality of Life by ≥ 10 points.

    Time frame: 30 days, 1 year, 2 years

  7. NYHA functional classification

    Improvement from baseline by ≥ 1 functional classification.

    Time frame: 30 days, 1 year, 2 years

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2022, 25 months.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's 25 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2020
First posted
Jul 9, 2020
StartActual
Aug 19, 2020
Primary completionActual
Sep 30, 2022
CompletionEst.
Dec 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04464876
Lead sponsor
InnovHeart
Responsible party
Sponsor
First posted
Jul 9, 2020
Start date
Aug 19, 2020
Primary completion
Sep 30, 2022
Completion
Dec 2024 (estimated)
Last update
May 22, 2024

Study contacts

Marie Steinbrink
study director · InnovHeart

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion